Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

NCCN Guidelines® Insights: Distress Management, Version 2.2023
Riba, Michelle B., Donovan, Kristine A. , Ahmed, Kauser , Braun, IIana, Breitbart, William , Brewer, Benjamin W. , Corbett, Cheyenne , Fleishman, Stewart B., Garcia, Sofia F. , Greenberg, Donna, Handzo, George , Hoofring, Laura, Hutchinson, Sean Z., Johns, Shelley A. , Keller, Jennifer A. , Kumar, Pallavi , Lahijani, Sheila , Martin, Sara , Niazi, Shehzad K. , Pailler, Megan E. , Parnes, Francine, Salman, Jaroslava, Scher, Eli D. , Schuster, Jessica , Teply, Melissa , Usher, A., Valentine, Alan , Vanderlan, Jessica, Lyons, Megan S., McMillian, Nicole R., Darlow, Susan, Garcia, Sofia F , Andersen, Barbara L. , Fann, Jesse R. , Huang, Chao‐Hui , Rao, Vinay P.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 8, 2023 | Volume: 21 | Issue: 5 | Pages: 450-457

10.6004/jnccn.2023.0026 | PMID 37156476 Get It

These NCCN Guidelines for Distress Management discuss the identification and treatment of psychosocial problems in patients with cancer. All patients experience some level of distress associated with a cancer diagnosis and the effects of the disease and its treatment regardless of the stage of disease. Clinically significant levels of distress occur in a subset of patients, and identification and treatment of distress are of utmost importance. The NCCN Distress Management Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights describe updates to the NCCN Distress Thermometer (DT) and Problem List, and to the treatment algorithms for patients with trauma- and stressor-related disorders.
International Epidemiology of Carbapenemase-Producing Escherichia coli
Boutzoukas, Angelique E , Komarow, Lauren , Chen, Liang , Hanson, Blake , Liu, Zhengyin , Mendoza, Soraya Salcedo, Ordóñez, Karen , Wang, Minggui , Ge, Lizhao , Giri, Abhigya, Hill, Carol , Baum, Keri, Kreiswirth, Barry N. , Patel, Robin , Arias, César A. , Chambers, Henry F. , Fowler, Vance G. , Investigators, Multi-Drug Resistant Organism Network, Souha, S Kanj, Jean, Francois Jabbour, Fujie, Zhang, Judith, J Lok, Robert, A Salata, Martin, Stryjewski, Valentina, Di Castelnuovo, Jose, Millan Oñate Gutierrez, Eric, Cober, Susan, Richter, Deverick, J Anderson, Beth, Evans, Carol, Hill, Heather, Reich, Keri, Baum, Rebekka, Arias, Vance, G Fowler, Karen, Ordoñez, Jesse, T Jacob, Li, Linghua , Barry, Neil, Samit, Desai, Erica, Herc, Ezequiel, Cordova, Maria, R Ponisio, Samuel, Vichez, Marisa, Laëtitia , Sandra, Valderrama, Jairo, Figueroa, Cesar, A Arias, An, Qiang , Diane, Panesso, Kirsten, R., Truc, Thanh, Jiachun, Su, Jiang, Jianping , Ming-gui, Wang, Xu, Xiaogang , Yang, Yang , Jose, M Munita, Maria, Spencer, Thamer, Alenazi, Robert, Alain, Steven, Hersch, Susan, Davies, Charles, Huskins, Kerry, G, Robin, Patel, Suzannah, Schmidt-Malan, Sara, Revolinski, Glenn, Wortmann, Robert, C Kalayjian, Greg, Weston, Belinda, Ostrowsky, Gopi, Patel, Daniel, E Furst, Angela, Kim, Julia, Garcia-Diaz, Soraya, Salcedo, John, Jeffy, Zhengyin, Liu, Andrew, Henderson, David, Louis, Qing, Xie, Keith, S Kaye, Gao, Hainv , Yu, Yunsong , Mary, Waters, Bettina, C Fries, Brandon, Eilertson, Kean, Lee Chew, Nares, Smitasin, Paul, Ananth Tambyah, Jason, Christopher, Anton, Peleg, Marcel, L. Saint, Lan-juan, LI , Lauren, Komarow, Lizhao, Ge, Scott, Evans, Todd, McCarty, Henry, Fitjerald , Omai, B Garner, Lilian, M Abbo, David, van Duin, Ebbing, Lautenbach, Jennifer, Harrington, Yohei, Doi, Darren, W Logan, Blake, Hanson, Jinnethe, Reyes, Maria, Virginia Villegas Botero, Lorena, Diaz, Federico, P., Ritu, Banerjee, Sorabh, Dhar, Michael, Joy S, Zhiyong, Zong, Stryjewski, Martín E. , Villegas, María Virginia , Wang, Minggui , Evans, Scott R , Patel, Robin , van Duin, David , Pérez, Federico , Jiang, Jianping , Boutzoukas, Angelique , Chen, Liang , Villegas, Maria Virginia , Kanj, Souha S. , Paterson, David L. , Evans, Scott , Bonomo, Robert A. , Kreiswirth, Barry N , Arias, César A. , Fowler, Vance G. , Investigators, Multi-Drug Resistant Organism Network, Souha, S Kanj, Fujie, Zhang, Jose, Millan-Onate, Eric, Cober, Barry, N Kreiswirth, Claudia, Manca, Marisa, L Sanchez, An, Q Dinh, Kirsten, Rydell, Hu, Fupin , Maria, Spencer-Sandino, Robert, A Bonomo, Steven, H Marshall, Susan, D Rudin, Glenn, Wortmann, Gopi, Patel, Zhengyin, Liu, David, L Paterson, Qing, Xie, Marimuthu, Kalisvar , Anton, Peleg, Henry, F Chambers, Ebbing, Lautenbach, Jennifer, H Han, Lorena, Diaz, Federico, Perez, Ritu, Banerjee, Zhiyong, Zong

Mayo Clinic

Clinical Infectious Diseases | May 8, 2023 | Volume: 77 | Issue: 4 | Pages: 499-509

10.1093/cid/ciad288 | PMID 37154071 Get It

Abstract Background Carbapenemase-producing (CP) Escherichia coli (CP-Ec) are a global public health threat. We aimed to describe the clinical and molecular epidemiology and outcomes of patients from several countries with CP-Ec isolates obtained from a prospective cohort. Methods Patients with CP-Ec were enrolled from 26 hospitals in 6 countries. Clinical data were collected, and isolates underwent whole-genome sequencing. Clinical and molecular features and outcomes associated with isolates with or without metallo-β-lactamases (MBLs) were compared. The primary outcome was desirability of outcome ranking (DOOR) at 30 days after the index culture. Results Of the 114 CP-Ec isolates in Consortium on resistance against carbapenems in Klebsiella and other Enterobacterales-2 (CRACKLE-2), 49 harbored an MBL, most commonly blaNDM-5 (38/49, 78%). Strong regional variations were noted with MBL-Ec predominantly found among patients in China (23/49). Clinically, MBL-Ec were more often from urine sources (49% vs 29%), less often met criteria for infection (39% vs 58%, P = .04), and had lower acuity of illness when compared with non–MBL-Ec. Among patients with infection, the probability of a better DOOR outcome for a randomly selected patient with MBL-Ec as compared with non–MBL-Ec was 62% (95% CI: 48.2–74.3%). Among infected patients, non–MBL-Ec had increased 30-day (26% vs 0%; P = .02) and 90-day (39% vs 0%; P = .001) mortality compared with MBL-Ec. Conclusions Emergence of CP-Ec was observed with important geographic variations. Bacterial characteristics, clinical presentations, and outcomes differed between MBL-Ec and non–MBL-Ec. Mortality was higher among non-MBL isolates, which were more frequently isolated from blood, but these findings may be confounded by regional variations.
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
Harrison, Claire , Nangalia, Jyoti , Boucher, Rebecca H. , Jackson, Aimee , Yap, Christina , O’Sullivan, Jennifer , Fox, Sonia, Ailts, Isaak , Dueck, Amylou C. , Geyer, Holly L. , Nadezhdin, Eugene, Curto‐García, Natalia , Green, Anna , Wilkins, Bridget S., Coppell, Jason, Laurie, John , Garg, Mamta , Ewing, Joanne, Knapper, Steven , Crowe, Josephine , Koutsavlis, Ioannis , Godfrey, Anna L. , Arami, Siamak , Drummond, Mark W., Clark, Fiona , Mead‐Harvey, Carolyn , Baxter, E. Joanna , Mead, Adam J. , Dueck, A. C. , Harrison, Claire N , Boucher, Rebecca , Mesa, Ruben , Dunn, William G , Garg, Mamta , Knapper, Steven , Crowe, Josephine , Koutsavlis, Ioannis , Arami, Siamak , Byrne, Jennifer , Baxter, Elizabeth Joanna , McMullin, Mary Frances , Mead, Adam J , Yap, Christina , Mesa, Ruben A. , Dunn, William G. , Chen, Frederick , Byrne, Jenny , McMullin, Mary Frances

Mayo Clinic

Journal of Clinical Oncology | May 1, 2023 | Volume: 41 | Issue: 19 | Pages: 3534-3544

10.1200/jco.22.01935 | PMID 37126762 Get It

PURPOSE Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV, ruxolitinib controls blood counts and improves symptoms. PATIENTS AND METHODS MAJIC-PV is a randomized phase II trial of ruxolitinib versus best available therapy (BAT) in patients resistant/intolerant to hydroxycarbamide (HC-INT/RES). Primary outcome was complete response (CR) within 1 year. Secondary outcomes included duration of response, event-free survival (EFS), symptom, and molecular response. RESULTS One hundred eighty patients were randomly assigned. CR was achieved in 40 (43%) patients on ruxolitinib versus 23 (26%) on BAT (odds ratio, 2.12; 90% CI, 1.25 to 3.60; P = .02). Duration of CR was superior for ruxolitinib (hazard ratio [HR], 0.38; 95% CI, 0.24 to 0.61; P < .001). Symptom responses were better with ruxolitinib and durable. EFS (major thrombosis, hemorrhage, transformation, and death) was superior for patients attaining CR within 1 year (HR, 0.41; 95% CI, 0.21 to 0.78; P = .01); and those on ruxolitinib (HR, 0.58; 95% CI, 0.35 to 0.94; P = .03). Serial analysis of JAK2V617F variant allele fraction revealed molecular response was more frequent with ruxolitinib and was associated with improved outcomes (progression-free survival [PFS] P = .001, EFS P = .001, overall survival P = .01) and clearance of JAK2V617F stem/progenitor cells. ASXL1 mutations predicted for adverse EFS (HR, 3.02; 95% CI, 1.47 to 6.17; P = .003). The safety profile of ruxolitinib was as previously reported. CONCLUSION The MAJIC-PV study demonstrates ruxolitinib treatment benefits HC-INT/RES PV patients with superior CR, and EFS as well as molecular response; importantly also demonstrating for the first time, to our knowledge, that molecular response is linked to EFS, PFS, and OS.
A Systematic Review of Methods Used to Determine the Work of Breathing during Exercise
Isautier, Jennifer , Hubbard, Colin D. , Morris, Sarah J. , Smith, Joshua R. , Duke, Joseph W. , Smith, Joshua R , Cross, Troy J. , Kelley, Eli F. , Hubbard, Colin D.

Mayo Clinic

Medicine & Science in Sports & Exercise | May 1, 2023 | Volume: 55 | Issue: 9 | Pages: 1672-1682

10.1249/mss.0000000000003187 | PMID 37126027 Get It

ABSTRACT Introduction Measurement of the work of breathing (Wb) during exercise provides useful insights into the energetics and mechanics of the respiratory muscles across a wide range of minute ventilations. The methods and analytical procedures used to calculate the Wb during exercise have yet to be critically appraised in the literature. Purpose The aim of this systematic review was to evaluate the quality of methods used to measure the Wb during exercise in the available literature. Methods We conducted an extensive search of three databases for studies that measured the Wb during exercise in adult humans. Data were extracted on participant characteristics, flow/volume and pressure devices, esophageal pressure (P oes ) catheters, and methods of Wb analysis. Results A total of 120 articles were included. Flow/volume sensors used were primarily pneumotachographs ( n = 85, 70.8%), whereas the most common pressure transducer was of the variable reluctance type ( n = 63, 52.5%). Esophageal pressure was frequently obtained via balloon-tipped catheters ( n = 114, 95.0%). Few studies mentioned calibration, frequency responses, and dynamic compensation of their measurement devices. The most popular method of measuring the Wb was pressure–volume integration ( n = 51, 42.5%), followed by the modified Campbell ( n = 28, 23.3%) and Dean & Visscher diagrams ( n = 26, 21.7%). Over one-third of studies did not report the methods used to process their pressure–volume data, and the majority (60.8%) of studies used the incorrect Wb units and/or failed to discuss the limitations of their Wb measurements. Conclusions The findings of this systematic review highlight the need for the development of a standardized approach for measuring Wb, which is informative, practical, and accessible for future researchers.
Diagnostic Value of Endobronchial Ultrasound Transbronchial Need Aspiration (EBUS-TBNA) in Multi-Focal Adenocarcinoma Patients With Pet Negative Hilar and Mediastinal Lymph Nodes
Al-Ghoula, F., Albitar, Hasan Ahmad Hasan , Duke, Jennifer D. , Peikert, Tobias, Edell, Eric S.

Mayo Clinic

A30. ALL THINGS INTERVENTIONAL PULMONARY A LIVELY POSTER DISCUSSION | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A1282-A1282

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a1282 Get It

A Case of Disseminated Nocardiosis in an Immunocompetent Host
Grassi, Angela R, Duke, Jennifer D. , Thomas, Charles F.

Mayo Clinic

C67. DON'T FORGET ABOUT THESE UNUSUAL LUNG INFECTIONS | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A5631-A5631

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5631 Get It

Papanicolaou test collection with the Papette brush or the spatula with cytobrush: A pragmatic study
O’Laughlin, Danielle , Strelow, Brittany , Fellows, Nicole, Stevens, Joy , Kelsey, Elizabeth A. , Fink, Stephanie, Peters, Sonya, Johnson, Jennifer, Houghton, Jaclyn P, Stolp, Anne, Tweedy, Johanna, DeJesus, Ramona S. , O'Laughlin, Danielle J , Strelow, Brittany A , Fellows, Nicole A, Stevens, Joy N, Fink, Stephanie R, Peters, Sonya M, Johnson, Jennifer A, Stolp, Anne M, Tweedy, Johanna M, DeJesus, R S , Fischer, Karen M.

Mayo Clinic

Women's Health | April 29, 2023 | Volume: 19 | Issue: No issue available | Pages: No page available

10.1177/17455057231170975 | PMID 37119034 Get It

Background: Cotesting with the Papanicolaou (Pap) and human papillomavirus tests detects most precancerous and cancerous lesions and increases the sensitivity for detecting high-grade precancerous and invasive cervical cancers compared with human papillomavirus testing alone. Objective: To compare the use of the Papette brush (hereafter Papette) to the traditional spatula with endocervical brush (cytobrush) for cervical cancer screening. Design: Pragmatic observational study. Methods: Adult women aged 21–64 years who were eligible for a Papanicolaou test at a Midwest Community Internal Medicine practice underwent cervical cancer screening using the Papette or spatula with cytobrush from 18 August 2021 through 1 February 2022. Cluster sampling was used across the practice. Pathology reports were then analyzed to compare the number of satisfactory versus unsatisfactory results between the two collection techniques. Results: We collected results for 756 Pap tests. The test results were satisfactory with the Papette 93.8% of the time compared with 93.0% for the spatula with cytobrush. Conclusion: The Papette is not inferior to a spatula with cytobrush as a collection method for Pap tests.
Cold Hands and Feet in Multiple System Atrophy – A Useful Diagnostic Marker? (P9-9.001)
Gehrking, Jade A., Gehrking, Tonette L., Sletten, David M., Suarez, Mariana, Low, Phillip A. , Singer, Wolfgang , Anderson, Jennifer

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000204227 Get It

Paraneoplastic and non-paraneoplastic limbic encephalitis: distinguishing features and outcomes (P7-5.031)
McCombe, Jennifer A. , Ζεκερίδου, Αναστασία , Thakolwiboon, Smathorn , Datta, Abhigyan , Madhavan, Ajay A. , Flanagan, Eoin P. , Pittock, Sean J. , McKeon, Andrew , Dubey, Divyanshu

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000203678 Get It